
Outset Medical (OM) Stock Forecast & Price Target
Outset Medical (OM) Analyst Ratings
Bulls say
Outset Medical Inc has demonstrated a strong demand for its products, evidenced by an expanding order pipeline that has shown positive progression from Q4 to Q1. The company is also on track to reach EBITDA positivity with anticipated sales of less than $200 million by 2028, indicating a clear path to profitability. Furthermore, management has indicated that they possess sufficient funds to support their growth and operational goals.
Bears say
Outset Medical Inc. faces a negative outlook primarily due to several critical risks that could impair its financial performance. The company is heavily reliant on the adoption of its single product, the Tablo system, with slower-than-anticipated adoption rates in both acute care and home settings presenting significant barriers to growth. Additionally, Outset Medical has not yet achieved profitability, and external macroeconomic factors may further disrupt its supply chain, raising concerns about its long-term viability in a competitive market.
This aggregate rating is based on analysts' research of Outset Medical and is not a guaranteed prediction by Public.com or investment advice.
Outset Medical (OM) Analyst Forecast & Price Prediction
Start investing in Outset Medical (OM)
Order type
Buy in
Order amount
Est. shares
0 shares